Finoriq research workspace
Viatris Inc (VTRS) SEC Filings & Filing Highlights
Viatris Inc. operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong. Review VTRS SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
- Company
- Viatris Inc (VTRS)
- Ticker
- VTRS
- Market Cap
- $19.8B
- Latest Price
- $16.98
- Industry
- Biotech & Pharma
Viatris Inc (VTRS) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Viatris Inc (VTRS).
| Event | Form | Date |
|---|---|---|
| Viatris Inc: Material agreementOn July 1, 2026 (the “Closing Date”), Viatris Inc. (“Viatris”) entered into an amended and restated term loan credit agreement (the “Amende... | 8-K1.01 | 2026-07-01 |
| Debt or FinancingDebt or Financing | 8-K2.03 | 2026-06-18 |
| Viatris Inc: Material agreementOn June 17, 2026, Viatris Inc. (“Viatris” or the “Company”) completed a public offering of €650,000,000 aggregate principal amount of its 4... | 8-K1.01 | 2026-06-18 |
| Viatris Inc: Corporate updateOn June 12, 2026, Viatris Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the several under... | 8-K8.01 | 2026-06-15 |
| The certified results of the matters voted on at the 2026 Annual Meeting are set forth below(a) On May 15, 2026, Viatris Inc. (“Viatris” or the “Company”) held its 2026 annual meeting of shareholders (the “2026 Annual Meeting”). At... | 8-K5.07 | 2026-05-15 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.